A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial that includes Gemcitabine 1,250mg/m2 to be administered over
approximately 30 minutes on days 1 and 8, every 21 days and Trastuzumab 8 mg/kg IV to be
administered over 90 minutes on day 1 of the first cycle, then 6mg/kg as a 30 minute infusion
administered on subsequent cycles.